ClinicalTrials.gg
RecruitingNCT06047912PURLUpdated Sep 21, 2023

Screening for Primary Aldosteronism in Hypertension With 24-hour URinary aLdosterone

An observational study in Hypertension, Primary Aldosteronism and Urine Aldosterone, sponsored by Dr Ian B Wilkinson. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by Dr Ian B Wilkinson · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
120
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 223 studies in Hypertension with a site in United Kingdom — 34 open to participants now, 43 under way, 7 of them phase 3. Hypertension · United Kingdom.

Planned enrollment
34th of 50
120 · median 200
Started
2023
with 12 others
Observational
50 of 223
14 open now
Primary completion
2024-09
later than 5 of 42 live
Registered
185th of 223
by date

Among the 223 studies in Hypertension with a site in United Kingdom, this one is the 34th largest by planned enrollment of the 50 observational ones that give a count, is one of 13 that started in 2023, is one of 50 observational ones, reaches primary completion later than 5 of the 42 other live ones, and was the 185th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

34 of the 223 studies in Hypertension with a site in United Kingdom are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 223 studies in Hypertension with a site in United Kingdom, or all of them as a file.
02

Study summary

This is an observational study compares the positivity rates of two tests for screening for primary aldosteronism: plasma aldosterone renin ratio and 24-hour urine aldosterone in patients with young-onset hypertension with or without other clinical features of primary aldosteronism.

Read the detailed description

Plasma aldosterone and renin measurements are subject to significant intra-individual variability, including variation related to posture, time of day and sodium balance. Aldosterone secretion is not constant and may be subject to diurnal variation. As such one-off testing of ARR, does not consider the salt status of the individual necessitating repetition of tests to ensure false negative or false positive test results are ruled out. The value of accumulated aldosterone in a 24-hour sample has the advantage that it does not depend on circadian variation. This pilot observational study will help establish the positivity rates of both standard plasma aldosterone renin ratio and 24-hour urine aldosterone, and the degree to which they correlate but will help establish if untargeted screening in young-onset hypertension is feasible and test the robustness of current standard guidelines for primary aldosteronism screening and case confirmation.

03

Conditions studied

  • Hypertension
  • Primary Aldosteronism
  • Urine Aldosterone
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

To enable the inclusion of a diverse population, representative of the UK in terms of ethnicity, and geographical and environmental factors that affect blood pressure and PA, we aim to conduct the study at several specialist hypertension sites in the UK. We will recruit patients referred to one of the study sites with hypertension (NICE definition) who fall into one of the following groups (cohorts):

Cohort 1: Adult patients (18-75 years of age) with onset hypertension (≤60 years of age) but without other obvious features of PA Cohort 2: Adult patients (18-75 years of age) with onset hypertension (≤60 years of age) with one of the features: low serum potassium, or resistant hypertension.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A patient will be eligible for inclusion in this trial only if all of the following criteria apply:

    • Aged 18 years and above.
    • Meets NICE criteria for a diagnosis of hypertension with an age of onset of hypertension between 18-60 years.
    • For cohort 2 (suspected primary aldosteronism): resistant hypertension, and/or hypertension with spontaneous or diuretic-induced hypokalaemia, and/or hypertension.

Exclusion criteria

Exclusion Criteria:

    • Severe hypertension (sustained blood pressure of >200/110 mmHg) or a history of known secondary hypertension other than PA.

      • to confirmatory testing with saline infusion or oral salt loading test as per standard clinical criteria such as known clinical diagnosis of heart failure, and/or chronic kidney disease stage 3b.
      • Known Pregnancy or breast feeding.
      • Lack of .
      • Any medical condition deemed unsuitable by investigator for participation in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Rates of positive and negative, Aldosterone renin ratio and 24-hr urine aldosterone in unselected patients with hypertension and in patients with suspected primary aldosteronism

    Time frame: 1 year

  2. Degree of agreement between a positive/negative ARR and a positive/negative 24-hr urine aldosterone

    Time frame: 1 year

Secondary outcomes

  1. Number of patients who required oral salt loading

    Time frame: 1 year

  2. The predictive value of a positive aldosterone renin ratio or 24-hr urine aldosterone with a positive confirmatory test

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Vascular Research Clinic, Adenbrooke's Centre of Clinical Investigation, Addenbrooke's Hospital
    Cambridge, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2023; primary completion for Sep 2024, 12 months later.

Of 348 non-industry observational studies under Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 111. This study's planned 12 months is below that.

Counting every sponsor, half of 429 studies reached it within 38 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2023
First posted
Sep 21, 2023
StartEst.
Sep 15, 2023
Primary completionEst.
Sep 30, 2024
CompletionEst.
Dec 30, 2024
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06047912
Lead sponsor
Dr Ian B Wilkinson
Responsible party
Dr Ian B Wilkinson (Chief Investigator, Cambridge University Hospitals NHS Foundation Trust) — Sponsor-investigator
First posted
Sep 21, 2023
Start date
Sep 15, 2023 (estimated)
Primary completion
Sep 30, 2024 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Sep 21, 2023

Study contacts

Spoorthy Kulkarni, MD, MRCP
Contact
cuh.purl@nhs.net
01223586865
Ian Wilkinson, DM, MRCP
study chair · University of Cambridge

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion